Novartis is said to near acquisition of Avidity Biosciences for more than $70 a share (NVS:NYSE)

Core Viewpoint - Novartis is in advanced discussions to acquire Avidity Biosciences, with an offer expected to exceed $70 per share [2] Company Summary - Novartis is a Swiss pharmaceutical company actively pursuing the acquisition of Avidity Biosciences, a U.S.-based company [2] - The acquisition discussions indicate Novartis's strategy to expand its portfolio and enhance its market position [2] Financial Details - The proposed offer for Avidity Biosciences is reported to be over $70 per share, reflecting a significant valuation for the target company [2]